Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Early Detection of Cancer | 72 | 2024 | 3201 | 6.130 |
Why?
|
Mammography | 48 | 2021 | 2430 | 3.550 |
Why?
|
Uterine Cervical Neoplasms | 26 | 2024 | 2020 | 2.810 |
Why?
|
Breast Neoplasms | 76 | 2024 | 21012 | 2.510 |
Why?
|
Primary Health Care | 32 | 2023 | 4686 | 2.400 |
Why?
|
Healthcare Disparities | 24 | 2024 | 3358 | 2.210 |
Why?
|
Colorectal Neoplasms | 27 | 2024 | 6935 | 2.110 |
Why?
|
Mass Screening | 41 | 2024 | 5428 | 2.030 |
Why?
|
Community Health Centers | 2 | 2024 | 461 | 1.450 |
Why?
|
Smoking Cessation | 10 | 2022 | 2056 | 1.420 |
Why?
|
Health Services Accessibility | 26 | 2021 | 5440 | 1.350 |
Why?
|
Colonoscopy | 10 | 2024 | 1394 | 1.280 |
Why?
|
Social Class | 13 | 2023 | 2004 | 1.160 |
Why?
|
Occult Blood | 9 | 2024 | 198 | 1.100 |
Why?
|
Tobacco Use Cessation | 2 | 2022 | 94 | 1.050 |
Why?
|
Diagnostic Self Evaluation | 2 | 2018 | 224 | 1.050 |
Why?
|
Telephone | 4 | 2018 | 627 | 1.030 |
Why?
|
Lung Neoplasms | 13 | 2023 | 13380 | 0.940 |
Why?
|
Reminder Systems | 3 | 2024 | 388 | 0.910 |
Why?
|
Breast | 6 | 2019 | 1967 | 0.880 |
Why?
|
Female | 206 | 2024 | 392644 | 0.880 |
Why?
|
United States | 90 | 2024 | 72334 | 0.870 |
Why?
|
Medically Underserved Area | 2 | 2024 | 254 | 0.840 |
Why?
|
Managed Care Programs | 9 | 2016 | 940 | 0.840 |
Why?
|
Middle Aged | 142 | 2024 | 220895 | 0.810 |
Why?
|
Maternal Welfare | 5 | 2007 | 112 | 0.790 |
Why?
|
Electronic Health Records | 14 | 2023 | 4811 | 0.780 |
Why?
|
Aged | 116 | 2024 | 169289 | 0.770 |
Why?
|
Delayed Diagnosis | 2 | 2023 | 463 | 0.760 |
Why?
|
Adverse Drug Reaction Reporting Systems | 5 | 2012 | 494 | 0.750 |
Why?
|
Adult | 141 | 2024 | 221177 | 0.730 |
Why?
|
Humans | 248 | 2024 | 761504 | 0.720 |
Why?
|
Ultrasonography, Mammary | 5 | 2017 | 239 | 0.720 |
Why?
|
Practice Guidelines as Topic | 14 | 2024 | 7390 | 0.720 |
Why?
|
Health Care Costs | 5 | 2022 | 3242 | 0.720 |
Why?
|
Health Communication | 1 | 2023 | 213 | 0.710 |
Why?
|
Health Status | 12 | 2012 | 4077 | 0.700 |
Why?
|
Papillomavirus Infections | 6 | 2024 | 1613 | 0.650 |
Why?
|
Delivery of Health Care | 12 | 2023 | 5336 | 0.640 |
Why?
|
Behavioral Risk Factor Surveillance System | 6 | 2021 | 209 | 0.640 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.630 |
Why?
|
Registries | 14 | 2020 | 8224 | 0.630 |
Why?
|
Preventive Medicine | 1 | 2020 | 246 | 0.630 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2018 | 4016 | 0.630 |
Why?
|
Prenatal Care | 9 | 2005 | 1139 | 0.620 |
Why?
|
Hyperkalemia | 1 | 2020 | 233 | 0.600 |
Why?
|
Counseling | 6 | 2024 | 1547 | 0.580 |
Why?
|
Medicaid | 7 | 2020 | 2818 | 0.560 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2022 | 942 | 0.560 |
Why?
|
Poverty | 8 | 2015 | 2698 | 0.550 |
Why?
|
Colposcopy | 5 | 2024 | 150 | 0.540 |
Why?
|
Health Care Surveys | 16 | 2018 | 2426 | 0.530 |
Why?
|
Massachusetts | 18 | 2024 | 8830 | 0.530 |
Why?
|
Pharmacists | 1 | 2018 | 260 | 0.530 |
Why?
|
Professional Role | 1 | 2018 | 314 | 0.510 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 1516 | 0.500 |
Why?
|
Prenatal Diagnosis | 1 | 2022 | 1265 | 0.500 |
Why?
|
Insurance, Health | 11 | 2019 | 2498 | 0.500 |
Why?
|
Prejudice | 4 | 2012 | 570 | 0.490 |
Why?
|
Health Services | 4 | 2012 | 752 | 0.480 |
Why?
|
Vaginal Smears | 10 | 2023 | 499 | 0.480 |
Why?
|
Residence Characteristics | 8 | 2024 | 2093 | 0.470 |
Why?
|
Male | 100 | 2024 | 360804 | 0.470 |
Why?
|
Insurance Claim Reporting | 2 | 2011 | 166 | 0.470 |
Why?
|
California | 10 | 2024 | 1429 | 0.470 |
Why?
|
Smoking | 7 | 2020 | 9053 | 0.470 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 1039 | 0.460 |
Why?
|
Health Status Disparities | 4 | 2020 | 1852 | 0.450 |
Why?
|
Medical Record Linkage | 2 | 2011 | 285 | 0.440 |
Why?
|
Neoplasms | 12 | 2023 | 22170 | 0.440 |
Why?
|
Information Storage and Retrieval | 2 | 2017 | 819 | 0.440 |
Why?
|
Health Services Research | 13 | 2016 | 1812 | 0.430 |
Why?
|
Nuclear Physics | 4 | 2014 | 75 | 0.430 |
Why?
|
Income | 4 | 2021 | 1877 | 0.430 |
Why?
|
Socioeconomic Factors | 25 | 2020 | 7827 | 0.420 |
Why?
|
Family Practice | 6 | 2005 | 512 | 0.420 |
Why?
|
State Health Plans | 3 | 2013 | 219 | 0.420 |
Why?
|
Physician-Patient Relations | 10 | 2018 | 3249 | 0.420 |
Why?
|
Attitude of Health Personnel | 3 | 2017 | 3889 | 0.410 |
Why?
|
Language | 2 | 2014 | 1540 | 0.400 |
Why?
|
Women's Health | 8 | 2022 | 2065 | 0.400 |
Why?
|
Aged, 80 and over | 34 | 2023 | 58976 | 0.390 |
Why?
|
Logistic Models | 24 | 2021 | 13255 | 0.390 |
Why?
|
Health Records, Personal | 1 | 2013 | 127 | 0.390 |
Why?
|
Product Labeling | 1 | 2012 | 76 | 0.390 |
Why?
|
Job Satisfaction | 3 | 2001 | 544 | 0.380 |
Why?
|
Depression, Postpartum | 2 | 2006 | 346 | 0.370 |
Why?
|
Medically Uninsured | 6 | 2020 | 836 | 0.370 |
Why?
|
Radiology Information Systems | 1 | 2015 | 529 | 0.370 |
Why?
|
Insurance, Pharmaceutical Services | 5 | 2008 | 348 | 0.360 |
Why?
|
Patient Acceptance of Health Care | 5 | 2020 | 3205 | 0.360 |
Why?
|
Postal Service | 3 | 2020 | 96 | 0.360 |
Why?
|
Nicotinic Agonists | 1 | 2012 | 265 | 0.350 |
Why?
|
Quinoxalines | 1 | 2012 | 296 | 0.350 |
Why?
|
Minority Groups | 3 | 2015 | 1203 | 0.350 |
Why?
|
Benzazepines | 1 | 2012 | 310 | 0.350 |
Why?
|
Housing | 2 | 2024 | 670 | 0.350 |
Why?
|
Attitude to Health | 5 | 2006 | 2025 | 0.350 |
Why?
|
Medicare | 11 | 2017 | 6770 | 0.340 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 2 | 2005 | 556 | 0.340 |
Why?
|
Internal Medicine | 5 | 2004 | 1051 | 0.340 |
Why?
|
Patient-Centered Care | 3 | 2016 | 1421 | 0.340 |
Why?
|
Risk Assessment | 15 | 2021 | 23995 | 0.340 |
Why?
|
Cross-Sectional Studies | 29 | 2023 | 26125 | 0.340 |
Why?
|
Breast Diseases | 3 | 2014 | 442 | 0.340 |
Why?
|
Clinical Coding | 1 | 2011 | 181 | 0.340 |
Why?
|
Educational Status | 8 | 2021 | 2522 | 0.330 |
Why?
|
Pregnancy | 18 | 2023 | 29874 | 0.330 |
Why?
|
Elementary Particles | 3 | 2014 | 52 | 0.330 |
Why?
|
Eligibility Determination | 1 | 2013 | 421 | 0.330 |
Why?
|
SEER Program | 3 | 2011 | 1450 | 0.330 |
Why?
|
Uterine Cervical Dysplasia | 2 | 2023 | 384 | 0.330 |
Why?
|
Physicians, Primary Care | 2 | 2017 | 623 | 0.320 |
Why?
|
Quality of Health Care | 7 | 2016 | 4330 | 0.320 |
Why?
|
Patient Participation | 4 | 2020 | 1444 | 0.320 |
Why?
|
Health Surveys | 3 | 2017 | 4061 | 0.320 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 926 | 0.320 |
Why?
|
Drug Prescriptions | 5 | 2008 | 1670 | 0.320 |
Why?
|
Data Collection | 9 | 2023 | 3322 | 0.320 |
Why?
|
Health Promotion | 3 | 2017 | 2214 | 0.310 |
Why?
|
Patient Satisfaction | 7 | 2004 | 3461 | 0.310 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2018 | 1085 | 0.310 |
Why?
|
Genetic Testing | 4 | 2017 | 3537 | 0.310 |
Why?
|
Fees, Pharmaceutical | 1 | 2008 | 66 | 0.310 |
Why?
|
Estrogen Replacement Therapy | 2 | 2006 | 1208 | 0.310 |
Why?
|
Documentation | 1 | 2014 | 897 | 0.310 |
Why?
|
Family Health | 1 | 2013 | 1257 | 0.300 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2471 | 0.300 |
Why?
|
Cohort Studies | 24 | 2021 | 41487 | 0.290 |
Why?
|
Papillomaviridae | 5 | 2023 | 1119 | 0.290 |
Why?
|
Prescription Drugs | 2 | 2015 | 631 | 0.290 |
Why?
|
Patient Compliance | 7 | 2018 | 2690 | 0.290 |
Why?
|
Hospices | 2 | 2008 | 245 | 0.290 |
Why?
|
Gene Expression Profiling | 2 | 2015 | 9420 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2021 | 10209 | 0.280 |
Why?
|
Guideline Adherence | 8 | 2024 | 2220 | 0.280 |
Why?
|
Medicare Part D | 2 | 2009 | 355 | 0.280 |
Why?
|
Health Care Reform | 2 | 2020 | 1247 | 0.280 |
Why?
|
Formularies as Topic | 1 | 2007 | 94 | 0.280 |
Why?
|
Preventive Health Services | 2 | 2002 | 567 | 0.280 |
Why?
|
Adolescent | 30 | 2021 | 88319 | 0.280 |
Why?
|
Insurance Coverage | 8 | 2019 | 1940 | 0.270 |
Why?
|
Gatekeeping | 2 | 2004 | 49 | 0.270 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5492 | 0.270 |
Why?
|
Young Adult | 20 | 2022 | 59243 | 0.260 |
Why?
|
Boston | 19 | 2024 | 9326 | 0.260 |
Why?
|
Diabetes Mellitus | 2 | 2021 | 5840 | 0.260 |
Why?
|
Ambulatory Care | 7 | 2020 | 2775 | 0.260 |
Why?
|
Medical Records Systems, Computerized | 2 | 2009 | 1192 | 0.260 |
Why?
|
Referral and Consultation | 8 | 2020 | 3600 | 0.260 |
Why?
|
Comorbidity | 7 | 2023 | 10508 | 0.250 |
Why?
|
Aftercare | 3 | 2023 | 914 | 0.250 |
Why?
|
Patient Selection | 3 | 2013 | 4244 | 0.250 |
Why?
|
Travel | 3 | 2016 | 796 | 0.250 |
Why?
|
South Dakota | 1 | 2024 | 32 | 0.240 |
Why?
|
Age Factors | 16 | 2023 | 18395 | 0.240 |
Why?
|
Hypnotics and Sedatives | 1 | 2012 | 1179 | 0.230 |
Why?
|
Health Status Indicators | 2 | 2007 | 970 | 0.230 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 431 | 0.230 |
Why?
|
Interferon-beta | 2 | 2005 | 345 | 0.230 |
Why?
|
Health Benefit Plans, Employee | 1 | 2007 | 333 | 0.230 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2005 | 513 | 0.230 |
Why?
|
Hunger | 1 | 2006 | 206 | 0.230 |
Why?
|
Prescription Fees | 1 | 2005 | 153 | 0.230 |
Why?
|
Maternal Behavior | 1 | 2006 | 307 | 0.230 |
Why?
|
Drug Costs | 3 | 2008 | 1183 | 0.220 |
Why?
|
Cost Savings | 2 | 2008 | 913 | 0.220 |
Why?
|
Elementary Particle Interactions | 2 | 2013 | 17 | 0.220 |
Why?
|
Models, Theoretical | 5 | 2014 | 3575 | 0.220 |
Why?
|
Retrospective Studies | 26 | 2024 | 80636 | 0.220 |
Why?
|
Magnetic Resonance Imaging | 11 | 2018 | 36426 | 0.210 |
Why?
|
Qualitative Research | 2 | 2024 | 3023 | 0.210 |
Why?
|
Mental Health | 1 | 2017 | 3250 | 0.210 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2005 | 664 | 0.210 |
Why?
|
Social Justice | 1 | 2007 | 478 | 0.210 |
Why?
|
Health Behavior | 3 | 2020 | 2643 | 0.210 |
Why?
|
Filgrastim | 1 | 2022 | 132 | 0.210 |
Why?
|
Family Characteristics | 3 | 2021 | 1004 | 0.200 |
Why?
|
Insurance Carriers | 1 | 2004 | 156 | 0.200 |
Why?
|
Quality Indicators, Health Care | 3 | 2008 | 1792 | 0.200 |
Why?
|
Risk Factors | 30 | 2021 | 74206 | 0.200 |
Why?
|
Interinstitutional Relations | 2 | 2020 | 236 | 0.200 |
Why?
|
Pregnant Women | 1 | 2007 | 566 | 0.200 |
Why?
|
Algorithms | 7 | 2021 | 14031 | 0.200 |
Why?
|
Bupropion | 1 | 2004 | 304 | 0.200 |
Why?
|
San Francisco | 4 | 2007 | 162 | 0.200 |
Why?
|
Germany | 3 | 2020 | 875 | 0.190 |
Why?
|
Evidence-Based Medicine | 6 | 2015 | 3688 | 0.190 |
Why?
|
Contraceptive Agents | 1 | 2003 | 144 | 0.190 |
Why?
|
Commerce | 1 | 2007 | 606 | 0.190 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2020 | 297 | 0.190 |
Why?
|
Hormone Replacement Therapy | 1 | 2007 | 751 | 0.190 |
Why?
|
Odds Ratio | 10 | 2018 | 9646 | 0.190 |
Why?
|
Pharmaceutical Preparations | 2 | 2008 | 1089 | 0.180 |
Why?
|
Professional Practice | 3 | 2018 | 313 | 0.180 |
Why?
|
Hospitals | 3 | 2007 | 3882 | 0.180 |
Why?
|
Follow-Up Studies | 10 | 2022 | 39106 | 0.180 |
Why?
|
Pyridines | 1 | 2012 | 2875 | 0.180 |
Why?
|
Employment | 1 | 2007 | 1118 | 0.170 |
Why?
|
Pregnancy Outcome | 4 | 2005 | 2921 | 0.170 |
Why?
|
Drugs, Generic | 1 | 2005 | 448 | 0.170 |
Why?
|
Appointments and Schedules | 1 | 2003 | 443 | 0.170 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2811 | 0.170 |
Why?
|
Milk, Human | 1 | 2004 | 486 | 0.160 |
Why?
|
Multivariate Analysis | 11 | 2015 | 12059 | 0.160 |
Why?
|
Cost Sharing | 3 | 2009 | 409 | 0.160 |
Why?
|
Paroxetine | 1 | 2020 | 182 | 0.160 |
Why?
|
Information Dissemination | 2 | 2006 | 1126 | 0.160 |
Why?
|
Reproduction | 1 | 2023 | 645 | 0.160 |
Why?
|
Sertraline | 1 | 2020 | 209 | 0.160 |
Why?
|
Needs Assessment | 2 | 2024 | 1139 | 0.160 |
Why?
|
Antidepressive Agents | 3 | 2020 | 2897 | 0.160 |
Why?
|
Body Mass Index | 10 | 2018 | 12953 | 0.160 |
Why?
|
Life Style | 5 | 2018 | 3917 | 0.160 |
Why?
|
Hospital Mortality | 2 | 2007 | 5294 | 0.150 |
Why?
|
Weight Gain | 2 | 2005 | 2348 | 0.150 |
Why?
|
Trust | 1 | 2003 | 530 | 0.150 |
Why?
|
Interprofessional Relations | 1 | 2004 | 990 | 0.150 |
Why?
|
Tobacco Smoke Pollution | 1 | 2004 | 819 | 0.150 |
Why?
|
Breast Feeding | 1 | 2006 | 1359 | 0.150 |
Why?
|
Efficiency | 1 | 2001 | 476 | 0.150 |
Why?
|
Patient Care | 2 | 2022 | 622 | 0.150 |
Why?
|
Antihypertensive Agents | 1 | 2007 | 2024 | 0.140 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 8002 | 0.140 |
Why?
|
Neutropenia | 1 | 2022 | 885 | 0.140 |
Why?
|
Risk Reduction Behavior | 4 | 2018 | 1112 | 0.140 |
Why?
|
4-Aminopyridine | 1 | 2017 | 80 | 0.140 |
Why?
|
Prospective Studies | 15 | 2024 | 54425 | 0.140 |
Why?
|
Confidence Intervals | 4 | 2006 | 2927 | 0.140 |
Why?
|
Potassium Channel Blockers | 1 | 2017 | 161 | 0.140 |
Why?
|
Computers, Handheld | 1 | 2018 | 210 | 0.140 |
Why?
|
Health Facilities | 3 | 2018 | 580 | 0.130 |
Why?
|
Time Factors | 11 | 2023 | 39967 | 0.130 |
Why?
|
Continuity of Patient Care | 4 | 2021 | 1069 | 0.130 |
Why?
|
Pharmacoepidemiology | 2 | 2018 | 350 | 0.130 |
Why?
|
Life Support Care | 2 | 1999 | 226 | 0.130 |
Why?
|
Vulnerable Populations | 2 | 2015 | 703 | 0.130 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 495 | 0.130 |
Why?
|
Hypertension | 4 | 2021 | 8540 | 0.130 |
Why?
|
Cross-Cultural Comparison | 1 | 2019 | 635 | 0.130 |
Why?
|
Reimbursement, Incentive | 1 | 2001 | 543 | 0.130 |
Why?
|
Diabetes, Gestational | 1 | 2005 | 1248 | 0.130 |
Why?
|
Pneumonia | 2 | 2007 | 2143 | 0.130 |
Why?
|
Professional Practice Location | 2 | 2007 | 56 | 0.130 |
Why?
|
Gift Giving | 1 | 2016 | 76 | 0.130 |
Why?
|
Government Programs | 1 | 2017 | 279 | 0.130 |
Why?
|
Longitudinal Studies | 8 | 2018 | 14605 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2022 | 2358 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2000 | 644 | 0.120 |
Why?
|
Self Report | 3 | 2020 | 3724 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2021 | 559 | 0.120 |
Why?
|
Pilot Projects | 7 | 2020 | 8631 | 0.120 |
Why?
|
Genetic Counseling | 2 | 2017 | 627 | 0.120 |
Why?
|
Sex Factors | 6 | 2017 | 10552 | 0.120 |
Why?
|
Self-Assessment | 1 | 2017 | 396 | 0.120 |
Why?
|
Neoplasm Staging | 4 | 2009 | 11121 | 0.120 |
Why?
|
Urinary Incontinence | 1 | 1999 | 489 | 0.120 |
Why?
|
Multiple Sclerosis | 5 | 2017 | 3220 | 0.120 |
Why?
|
Birth Certificates | 1 | 1994 | 71 | 0.120 |
Why?
|
Medical History Taking | 3 | 2013 | 774 | 0.120 |
Why?
|
Pregnancy Complications | 3 | 2005 | 2947 | 0.120 |
Why?
|
Physician Incentive Plans | 1 | 2016 | 164 | 0.120 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 1999 | 2199 | 0.120 |
Why?
|
Depression | 4 | 2020 | 8124 | 0.120 |
Why?
|
Hypoglycemic Agents | 2 | 2018 | 3085 | 0.120 |
Why?
|
Diagnostic Services | 2 | 2004 | 34 | 0.120 |
Why?
|
Communicable Disease Control | 1 | 2021 | 846 | 0.120 |
Why?
|
Pandemics | 4 | 2022 | 8654 | 0.110 |
Why?
|
Infant, Low Birth Weight | 2 | 1997 | 870 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2015 | 203 | 0.110 |
Why?
|
Risk | 4 | 2016 | 9610 | 0.110 |
Why?
|
Health Care Sector | 2 | 2006 | 195 | 0.110 |
Why?
|
Carcinoma, Lobular | 1 | 2018 | 481 | 0.110 |
Why?
|
Oncogene Fusion | 1 | 2013 | 81 | 0.110 |
Why?
|
Telemedicine | 2 | 2021 | 3051 | 0.110 |
Why?
|
Palliative Care | 1 | 2008 | 3598 | 0.110 |
Why?
|
Mesons | 1 | 2013 | 31 | 0.110 |
Why?
|
Reference Standards | 1 | 2017 | 1003 | 0.110 |
Why?
|
Community-Institutional Relations | 1 | 2015 | 206 | 0.110 |
Why?
|
Natural Language Processing | 1 | 2022 | 1162 | 0.110 |
Why?
|
Primary Prevention | 1 | 2001 | 1186 | 0.110 |
Why?
|
Video Recording | 1 | 2018 | 966 | 0.110 |
Why?
|
Immunosuppressive Agents | 2 | 2005 | 4174 | 0.110 |
Why?
|
Obesity | 6 | 2017 | 12947 | 0.110 |
Why?
|
Peptides | 1 | 2005 | 4358 | 0.110 |
Why?
|
Academic Medical Centers | 3 | 2020 | 2759 | 0.110 |
Why?
|
Polypharmacy | 1 | 2015 | 306 | 0.110 |
Why?
|
Receptor, trkA | 1 | 2013 | 159 | 0.100 |
Why?
|
Communication | 3 | 2018 | 3873 | 0.100 |
Why?
|
Advance Directives | 2 | 1999 | 249 | 0.100 |
Why?
|
Community Health Services | 1 | 2017 | 656 | 0.100 |
Why?
|
Radiology | 2 | 2018 | 2113 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2011 | 3514 | 0.100 |
Why?
|
Premature Birth | 1 | 2005 | 1782 | 0.100 |
Why?
|
Information Systems | 1 | 1994 | 396 | 0.100 |
Why?
|
Analgesics, Opioid | 1 | 2008 | 3808 | 0.100 |
Why?
|
Medical Assistance | 1 | 1993 | 108 | 0.100 |
Why?
|
Standard of Care | 1 | 2016 | 551 | 0.100 |
Why?
|
Piperazines | 1 | 2003 | 2523 | 0.100 |
Why?
|
Health Personnel | 3 | 2022 | 3335 | 0.100 |
Why?
|
Health Expenditures | 3 | 2015 | 2366 | 0.100 |
Why?
|
Quality Assurance, Health Care | 5 | 2008 | 2169 | 0.100 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 337 | 0.100 |
Why?
|
Reproducibility of Results | 5 | 2018 | 20098 | 0.090 |
Why?
|
Program Evaluation | 2 | 2016 | 2495 | 0.090 |
Why?
|
Texas | 2 | 2024 | 404 | 0.090 |
Why?
|
Medical Records | 4 | 2005 | 1408 | 0.090 |
Why?
|
Syphilis Serodiagnosis | 1 | 1990 | 37 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2020 | 1797 | 0.090 |
Why?
|
Genes, erbB-2 | 1 | 2011 | 162 | 0.090 |
Why?
|
Censuses | 2 | 2014 | 202 | 0.090 |
Why?
|
Anxiety | 2 | 2005 | 4573 | 0.090 |
Why?
|
Morbidity | 1 | 2016 | 1750 | 0.090 |
Why?
|
Quality of Life | 3 | 2021 | 13367 | 0.090 |
Why?
|
Pharmacopoeias as Topic | 1 | 2009 | 16 | 0.090 |
Why?
|
Speech Recognition Software | 1 | 2010 | 74 | 0.090 |
Why?
|
Observer Variation | 1 | 2016 | 2606 | 0.090 |
Why?
|
Communication Barriers | 1 | 1993 | 413 | 0.080 |
Why?
|
Air Pollutants | 1 | 2004 | 2896 | 0.080 |
Why?
|
Chronic Disease | 2 | 2020 | 9318 | 0.080 |
Why?
|
Medical Audit | 1 | 2011 | 453 | 0.080 |
Why?
|
Population Surveillance | 3 | 2016 | 2598 | 0.080 |
Why?
|
Obstetric Labor, Premature | 3 | 1999 | 272 | 0.080 |
Why?
|
Physicians | 2 | 2013 | 4591 | 0.080 |
Why?
|
Proportional Hazards Models | 7 | 2019 | 12463 | 0.080 |
Why?
|
Tumor Virus Infections | 1 | 1992 | 438 | 0.080 |
Why?
|
Biopsy | 2 | 2018 | 6766 | 0.080 |
Why?
|
Hospitalization | 5 | 2008 | 10723 | 0.080 |
Why?
|
Pharmacies | 2 | 2008 | 169 | 0.080 |
Why?
|
Comprehension | 1 | 2014 | 621 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2018 | 2161 | 0.080 |
Why?
|
Gene Rearrangement | 1 | 2013 | 1125 | 0.080 |
Why?
|
Obstetrics | 1 | 1995 | 665 | 0.080 |
Why?
|
Ovarian Neoplasms | 3 | 2017 | 4876 | 0.080 |
Why?
|
New Jersey | 1 | 2008 | 295 | 0.080 |
Why?
|
Taiwan | 2 | 2020 | 521 | 0.080 |
Why?
|
Physicians, Family | 1 | 2010 | 350 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1188 | 0.080 |
Why?
|
Adenoma | 1 | 2018 | 2160 | 0.070 |
Why?
|
Syphilis | 1 | 1990 | 243 | 0.070 |
Why?
|
Directive Counseling | 1 | 2009 | 170 | 0.070 |
Why?
|
Fractures, Bone | 1 | 2020 | 2046 | 0.070 |
Why?
|
Protons | 1 | 2013 | 1116 | 0.070 |
Why?
|
Pennsylvania | 1 | 2008 | 613 | 0.070 |
Why?
|
Psychology, Social | 1 | 2007 | 52 | 0.070 |
Why?
|
Treatment Outcome | 9 | 2008 | 64680 | 0.070 |
Why?
|
Cardiovascular Diseases | 4 | 2021 | 15500 | 0.070 |
Why?
|
Negotiating | 1 | 2008 | 150 | 0.070 |
Why?
|
Advisory Committees | 2 | 2024 | 787 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2020 | 22176 | 0.070 |
Why?
|
Decision Making | 3 | 2014 | 3929 | 0.070 |
Why?
|
Maternal-Child Health Centers | 1 | 2006 | 42 | 0.070 |
Why?
|
Prostatic Neoplasms | 4 | 2022 | 11118 | 0.070 |
Why?
|
Drug and Narcotic Control | 1 | 2007 | 144 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2243 | 0.070 |
Why?
|
Poisson Distribution | 1 | 2007 | 504 | 0.070 |
Why?
|
Endometrial Neoplasms | 2 | 2009 | 1366 | 0.070 |
Why?
|
Marital Status | 1 | 2007 | 426 | 0.070 |
Why?
|
Clinical Competence | 3 | 2024 | 4792 | 0.070 |
Why?
|
Cesarean Section | 2 | 1999 | 1396 | 0.060 |
Why?
|
Patients | 1 | 2012 | 907 | 0.060 |
Why?
|
Fibrocystic Breast Disease | 1 | 2005 | 103 | 0.060 |
Why?
|
DNA, Viral | 1 | 1992 | 2202 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2002 | 3416 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3429 | 0.060 |
Why?
|
United States Food and Drug Administration | 2 | 2010 | 1664 | 0.060 |
Why?
|
Terminally Ill | 1 | 2007 | 240 | 0.060 |
Why?
|
Prevalence | 3 | 2015 | 15732 | 0.060 |
Why?
|
Cerebrovascular Disorders | 1 | 1991 | 1474 | 0.060 |
Why?
|
Drug Utilization | 2 | 2008 | 1188 | 0.060 |
Why?
|
Drug Therapy | 1 | 2007 | 503 | 0.060 |
Why?
|
Postnatal Care | 1 | 2006 | 262 | 0.060 |
Why?
|
Product Packaging | 1 | 2004 | 23 | 0.060 |
Why?
|
Health Maintenance Organizations | 2 | 2000 | 659 | 0.060 |
Why?
|
Benchmarking | 2 | 2008 | 1045 | 0.060 |
Why?
|
Medical Oncology | 2 | 2022 | 2321 | 0.060 |
Why?
|
Research Design | 5 | 2020 | 6180 | 0.060 |
Why?
|
Likelihood Functions | 1 | 2007 | 992 | 0.050 |
Why?
|
Preconception Care | 1 | 2005 | 141 | 0.050 |
Why?
|
Canada | 2 | 2019 | 2122 | 0.050 |
Why?
|
Foreign Medical Graduates | 1 | 2003 | 77 | 0.050 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2004 | 116 | 0.050 |
Why?
|
Policy Making | 1 | 2007 | 542 | 0.050 |
Why?
|
Waiting Lists | 1 | 2007 | 765 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3084 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3204 | 0.050 |
Why?
|
Lung | 4 | 2022 | 10000 | 0.050 |
Why?
|
Interviews as Topic | 3 | 2006 | 2696 | 0.050 |
Why?
|
Survivors | 1 | 2012 | 2371 | 0.050 |
Why?
|
Observation | 1 | 2003 | 310 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 1994 | 2491 | 0.050 |
Why?
|
Survival Rate | 1 | 2016 | 12725 | 0.050 |
Why?
|
Time Management | 1 | 2001 | 52 | 0.050 |
Why?
|
Rural Population | 2 | 2015 | 2285 | 0.050 |
Why?
|
Deductibles and Coinsurance | 1 | 2004 | 316 | 0.050 |
Why?
|
Child | 4 | 2022 | 80153 | 0.050 |
Why?
|
Financing, Personal | 1 | 2004 | 309 | 0.050 |
Why?
|
Infant, Newborn | 6 | 2006 | 26198 | 0.050 |
Why?
|
Risk-Taking | 1 | 2007 | 1038 | 0.050 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2001 | 66 | 0.050 |
Why?
|
Mass Media | 1 | 2004 | 303 | 0.050 |
Why?
|
Receptor, erbB-2 | 2 | 2009 | 2557 | 0.050 |
Why?
|
Medication Adherence | 1 | 2012 | 2176 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3092 | 0.040 |
Why?
|
Biological Products | 1 | 2009 | 914 | 0.040 |
Why?
|
Physical Fitness | 1 | 2005 | 743 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 3 | 2017 | 17904 | 0.040 |
Why?
|
Sulfones | 1 | 2003 | 448 | 0.040 |
Why?
|
Professional-Patient Relations | 1 | 2005 | 726 | 0.040 |
Why?
|
Hospice Care | 1 | 2007 | 678 | 0.040 |
Why?
|
Genetic Techniques | 1 | 2003 | 427 | 0.040 |
Why?
|
Food Supply | 1 | 2006 | 544 | 0.040 |
Why?
|
Disability Evaluation | 2 | 2005 | 1835 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 629 | 0.040 |
Why?
|
Self Concept | 1 | 2005 | 1045 | 0.040 |
Why?
|
Models, Statistical | 2 | 2021 | 5079 | 0.040 |
Why?
|
Age Distribution | 3 | 2015 | 2880 | 0.040 |
Why?
|
Purines | 1 | 2003 | 607 | 0.040 |
Why?
|
Saliva | 1 | 2004 | 828 | 0.040 |
Why?
|
Cytological Techniques | 1 | 2021 | 218 | 0.040 |
Why?
|
Community-Acquired Infections | 1 | 2003 | 469 | 0.040 |
Why?
|
Emigration and Immigration | 2 | 2012 | 397 | 0.040 |
Why?
|
Physicians, Women | 1 | 2005 | 508 | 0.040 |
Why?
|
Pregnancy, High-Risk | 1 | 1999 | 122 | 0.040 |
Why?
|
Patient Discharge | 2 | 2007 | 3443 | 0.040 |
Why?
|
Carcinoma, Small Cell | 1 | 2001 | 420 | 0.040 |
Why?
|
Incidence | 5 | 2018 | 21353 | 0.040 |
Why?
|
Total Quality Management | 1 | 2000 | 265 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3801 | 0.040 |
Why?
|
Urban Population | 1 | 2007 | 2036 | 0.040 |
Why?
|
Hysterectomy | 1 | 2004 | 857 | 0.040 |
Why?
|
Health Education | 1 | 2005 | 1052 | 0.040 |
Why?
|
Community Networks | 1 | 2000 | 201 | 0.040 |
Why?
|
New Hampshire | 1 | 2018 | 175 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2226 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14666 | 0.040 |
Why?
|
Postpartum Period | 1 | 2005 | 1173 | 0.040 |
Why?
|
Urodynamics | 1 | 1999 | 346 | 0.040 |
Why?
|
Prognosis | 7 | 2020 | 29625 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 851 | 0.040 |
Why?
|
Fee-for-Service Plans | 1 | 2002 | 700 | 0.040 |
Why?
|
Office Visits | 2 | 2016 | 595 | 0.040 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15266 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2022 | 1189 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1668 | 0.030 |
Why?
|
Pregnancy Trimester, Third | 1 | 1999 | 583 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 1980 | 517 | 0.030 |
Why?
|
Maternal Age | 1 | 1999 | 809 | 0.030 |
Why?
|
United States Public Health Service | 1 | 1996 | 31 | 0.030 |
Why?
|
Linear Models | 2 | 2004 | 5871 | 0.030 |
Why?
|
North America | 1 | 2020 | 1276 | 0.030 |
Why?
|
Quebec | 1 | 2016 | 141 | 0.030 |
Why?
|
Parity | 1 | 1999 | 927 | 0.030 |
Why?
|
Confidentiality | 1 | 2020 | 609 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2009 | 13639 | 0.030 |
Why?
|
Magnesium | 1 | 1999 | 804 | 0.030 |
Why?
|
Mental Health Services | 1 | 2007 | 1730 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2018 | 12148 | 0.030 |
Why?
|
Mothers | 1 | 2006 | 2198 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2002 | 1141 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2004 | 1589 | 0.030 |
Why?
|
Online Systems | 1 | 2016 | 182 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1702 | 0.030 |
Why?
|
Asthma | 1 | 1994 | 6234 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2016 | 573 | 0.030 |
Why?
|
Body Weight | 1 | 2005 | 4618 | 0.030 |
Why?
|
Behavior Therapy | 1 | 2020 | 879 | 0.030 |
Why?
|
Delivery Rooms | 1 | 1994 | 38 | 0.030 |
Why?
|
Transportation | 1 | 2016 | 217 | 0.030 |
Why?
|
Hospital Charges | 1 | 1996 | 350 | 0.030 |
Why?
|
Social Responsibility | 1 | 2017 | 386 | 0.030 |
Why?
|
Tomography, Emission-Computed | 1 | 1997 | 1122 | 0.030 |
Why?
|
Erythropoiesis | 1 | 1998 | 683 | 0.030 |
Why?
|
Adenocarcinoma | 2 | 2001 | 6346 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2000 | 935 | 0.030 |
Why?
|
Specialty Boards | 1 | 1995 | 235 | 0.030 |
Why?
|
Influenza Vaccines | 1 | 2001 | 768 | 0.030 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2013 | 317 | 0.030 |
Why?
|
Scoliosis | 1 | 2000 | 741 | 0.030 |
Why?
|
Biopsy, Fine-Needle | 1 | 2018 | 1118 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2022 | 2469 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2017 | 805 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2022 | 6534 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9177 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 1991 | 5127 | 0.030 |
Why?
|
Data Interpretation, Statistical | 2 | 2018 | 2691 | 0.030 |
Why?
|
Databases, Factual | 2 | 2018 | 7967 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 1999 | 940 | 0.030 |
Why?
|
Regression Analysis | 2 | 1993 | 6343 | 0.030 |
Why?
|
Sociology, Medical | 1 | 2012 | 62 | 0.020 |
Why?
|
Outpatients | 1 | 2000 | 1597 | 0.020 |
Why?
|
Cholesterol | 1 | 2001 | 2904 | 0.020 |
Why?
|
Hospitals, Public | 1 | 1993 | 202 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2014 | 957 | 0.020 |
Why?
|
Insurance Claim Review | 1 | 2016 | 741 | 0.020 |
Why?
|
Social Identification | 1 | 2012 | 108 | 0.020 |
Why?
|
Zidovudine | 1 | 1993 | 624 | 0.020 |
Why?
|
Hypolipidemic Agents | 1 | 2015 | 609 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2017 | 1155 | 0.020 |
Why?
|
Injury Severity Score | 1 | 1994 | 1045 | 0.020 |
Why?
|
Safety Management | 1 | 2016 | 760 | 0.020 |
Why?
|
Alcohol Drinking | 2 | 2018 | 4028 | 0.020 |
Why?
|
Disease Progression | 2 | 2005 | 13506 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1242 | 0.020 |
Why?
|
Homosexuality | 1 | 1990 | 267 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 2001 | 2915 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1648 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2013 | 1435 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2001 | 1923 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2004 | 4486 | 0.020 |
Why?
|
Trauma Centers | 1 | 1994 | 937 | 0.020 |
Why?
|
Immunotherapy | 1 | 2004 | 4652 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6484 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 1993 | 1156 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2015 | 1733 | 0.020 |
Why?
|
Genotype | 1 | 2003 | 12990 | 0.020 |
Why?
|
Culture | 1 | 2012 | 623 | 0.020 |
Why?
|
Brain Diseases | 1 | 1997 | 1545 | 0.020 |
Why?
|
Infant, Premature | 1 | 1997 | 2107 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2510 | 0.020 |
Why?
|
Software | 2 | 2018 | 4434 | 0.020 |
Why?
|
Florida | 1 | 2008 | 431 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 1175 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1990 | 1596 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 1998 | 3612 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2010 | 15842 | 0.020 |
Why?
|
Motivation | 1 | 2016 | 2006 | 0.020 |
Why?
|
Length of Stay | 2 | 1996 | 6425 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2001 | 4026 | 0.020 |
Why?
|
Reference Values | 3 | 2002 | 4920 | 0.020 |
Why?
|
Infant | 2 | 2006 | 36192 | 0.020 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2006 | 132 | 0.020 |
Why?
|
Breast Self-Examination | 1 | 2005 | 33 | 0.020 |
Why?
|
Glucose | 1 | 1997 | 4346 | 0.020 |
Why?
|
Organizational Innovation | 1 | 2008 | 537 | 0.020 |
Why?
|
Disease Management | 1 | 2015 | 2508 | 0.010 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1997 | 2155 | 0.010 |
Why?
|
Women | 1 | 2006 | 223 | 0.010 |
Why?
|
HIV Infections | 1 | 1990 | 17351 | 0.010 |
Why?
|
Acute Disease | 1 | 1994 | 7237 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2004 | 641 | 0.010 |
Why?
|
Altitude | 1 | 1984 | 163 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2003 | 15936 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2013 | 2898 | 0.010 |
Why?
|
Cost Control | 1 | 2005 | 628 | 0.010 |
Why?
|
Physical Examination | 1 | 2009 | 1255 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3763 | 0.010 |
Why?
|
Selection Bias | 1 | 2004 | 359 | 0.010 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2004 | 254 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5247 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2005 | 368 | 0.010 |
Why?
|
Exercise | 1 | 2018 | 5890 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11742 | 0.010 |
Why?
|
Tamoxifen | 1 | 2006 | 965 | 0.010 |
Why?
|
Critical Care | 1 | 1994 | 2696 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17635 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3530 | 0.010 |
Why?
|
Management Quality Circles | 1 | 2000 | 20 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2009 | 3595 | 0.010 |
Why?
|
Institutional Management Teams | 1 | 2000 | 31 | 0.010 |
Why?
|
Thoracoplasty | 1 | 2000 | 15 | 0.010 |
Why?
|
Sex Distribution | 1 | 2005 | 2281 | 0.010 |
Why?
|
Tocolysis | 1 | 1999 | 18 | 0.010 |
Why?
|
Quality Control | 1 | 2003 | 832 | 0.010 |
Why?
|
Cations | 1 | 1999 | 238 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1980 | 882 | 0.010 |
Why?
|
Gynecology | 1 | 2004 | 526 | 0.010 |
Why?
|
Fetal Membranes, Premature Rupture | 1 | 1999 | 137 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2005 | 1386 | 0.010 |
Why?
|
Hemoglobins | 1 | 1984 | 1525 | 0.010 |
Why?
|
Arthrodesis | 1 | 2000 | 186 | 0.010 |
Why?
|
Electrocardiography | 1 | 1991 | 6377 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1990 | 4369 | 0.010 |
Why?
|
Activities of Daily Living | 2 | 1997 | 2421 | 0.010 |
Why?
|
Antibodies, Anticardiolipin | 1 | 1997 | 62 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 5671 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20570 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16981 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2001 | 1129 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1990 | 3080 | 0.010 |
Why?
|
Postoperative Complications | 1 | 1999 | 15631 | 0.010 |
Why?
|
Vertebrates | 1 | 1998 | 227 | 0.010 |
Why?
|
Feedback | 1 | 2000 | 791 | 0.010 |
Why?
|
Computer Communication Networks | 1 | 1998 | 293 | 0.010 |
Why?
|
Motor Activity | 1 | 2005 | 2715 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2001 | 1271 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2000 | 1682 | 0.010 |
Why?
|
Bone Transplantation | 1 | 2000 | 929 | 0.010 |
Why?
|
Infant Mortality | 1 | 1999 | 759 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6310 | 0.010 |
Why?
|
Resuscitation | 1 | 1999 | 673 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2000 | 2850 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2001 | 2208 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 6075 | 0.010 |
Why?
|
Mutation | 1 | 2017 | 30052 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2000 | 1505 | 0.010 |
Why?
|
Placebos | 1 | 1997 | 1667 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10766 | 0.010 |
Why?
|
Alleles | 1 | 2003 | 6863 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6228 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2001 | 6814 | 0.010 |
Why?
|
Gestational Age | 1 | 1999 | 3577 | 0.010 |
Why?
|
Pre-Eclampsia | 1 | 1999 | 1231 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1980 | 4915 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2000 | 2319 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2001 | 3466 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2001 | 11076 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2003 | 12795 | 0.000 |
Why?
|
Genetic Variation | 1 | 2003 | 6567 | 0.000 |
Why?
|
Diet | 1 | 2005 | 8075 | 0.000 |
Why?
|
Calcium | 1 | 1999 | 5722 | 0.000 |
Why?
|
Bolivia | 1 | 1984 | 22 | 0.000 |
Why?
|
Survival Analysis | 1 | 1997 | 10090 | 0.000 |
Why?
|
Neuropsychological Tests | 1 | 1997 | 7045 | 0.000 |
Why?
|
Polycythemia | 1 | 1984 | 124 | 0.000 |
Why?
|
Transferrin | 1 | 1984 | 283 | 0.000 |
Why?
|
Hematocrit | 1 | 1984 | 623 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1997 | 12341 | 0.000 |
Why?
|
Neurons | 1 | 1997 | 9463 | 0.000 |
Why?
|
Iron | 1 | 1984 | 1793 | 0.000 |
Why?
|
Anemia | 1 | 1984 | 1509 | 0.000 |
Why?
|
Brain | 1 | 1997 | 27112 | 0.000 |
Why?
|
Animals | 1 | 1998 | 168459 | 0.000 |
Why?
|